TY - JOUR
T1 - Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
AU - Reinecke, Maria
AU - Brear, Paul
AU - Vornholz, Larsen
AU - Berger, Benedict Tilmann
AU - Seefried, Florian
AU - Wilhelm, Stephanie
AU - Samaras, Patroklos
AU - Gyenis, Laszlo
AU - Litchfield, David William
AU - Médard, Guillaume
AU - Müller, Susanne
AU - Ruland, Jürgen
AU - Hyvönen, Marko
AU - Wilhelm, Mathias
AU - Kuster, Bernhard
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2024/5
Y1 - 2024/5
N2 - Medicinal chemistry has discovered thousands of potent protein and lipid kinase inhibitors. These may be developed into therapeutic drugs or chemical probes to study kinase biology. Because of polypharmacology, a large part of the human kinome currently lacks selective chemical probes. To discover such probes, we profiled 1,183 compounds from drug discovery projects in lysates of cancer cell lines using Kinobeads. The resulting 500,000 compound–target interactions are available in ProteomicsDB and we exemplify how this molecular resource may be used. For instance, the data revealed several hundred reasonably selective compounds for 72 kinases. Cellular assays validated GSK986310C as a candidate SYK (spleen tyrosine kinase) probe and X-ray crystallography uncovered the structural basis for the observed selectivity of the CK2 inhibitor GW869516X. Compounds targeting PKN3 were discovered and phosphoproteomics identified substrates that indicate target engagement in cells. We anticipate that this molecular resource will aid research in drug discovery and chemical biology. (Figure presented.).
AB - Medicinal chemistry has discovered thousands of potent protein and lipid kinase inhibitors. These may be developed into therapeutic drugs or chemical probes to study kinase biology. Because of polypharmacology, a large part of the human kinome currently lacks selective chemical probes. To discover such probes, we profiled 1,183 compounds from drug discovery projects in lysates of cancer cell lines using Kinobeads. The resulting 500,000 compound–target interactions are available in ProteomicsDB and we exemplify how this molecular resource may be used. For instance, the data revealed several hundred reasonably selective compounds for 72 kinases. Cellular assays validated GSK986310C as a candidate SYK (spleen tyrosine kinase) probe and X-ray crystallography uncovered the structural basis for the observed selectivity of the CK2 inhibitor GW869516X. Compounds targeting PKN3 were discovered and phosphoproteomics identified substrates that indicate target engagement in cells. We anticipate that this molecular resource will aid research in drug discovery and chemical biology. (Figure presented.).
UR - http://www.scopus.com/inward/record.url?scp=85175266077&partnerID=8YFLogxK
U2 - 10.1038/s41589-023-01459-3
DO - 10.1038/s41589-023-01459-3
M3 - Article
AN - SCOPUS:85175266077
SN - 1552-4450
VL - 20
SP - 577
EP - 585
JO - Nature Chemical Biology
JF - Nature Chemical Biology
IS - 5
ER -